China NMPA to Tighten Full-Chain Drug Safety Oversight in 15th Five-Year Plan

The signal here is regulatory breadth, not any single rule: pairing device law revision and TCM protection with a new pharmacopoeia and frontier standards like brain-computer interfaces suggests China is trying to build one compliance framework that covers legacy medicines and emerging tech alike. For device makers, TCM producers and developers of neurotech, the operative question is how much of this lands as binding rules versus standards that shape procurement and approvals. Whether the 2030 pharmacopoeia and the frontier-field standards move on the same timeline is the open question worth watching.